<DOC>
	<DOCNO>NCT01324063</DOCNO>
	<brief_summary>RATIONALE : Patient abstract available PURPOSE : Patient abstract available</brief_summary>
	<brief_title>A Randomized Phase III Study Intensive Consolidation With High Dose Cytosine Arabinoside Acute Myelogenous Leukemia ( AML-8B )</brief_title>
	<detailed_description>OBJECTIVES : I. Assess value ( term disease-free survival overall survival ) short intensive consolidation high-dose cytosine arabinoside patient acute myelogenous leukemia achieve complete remission induction daunorubicin cytosine arabinoside . II . Assess toxicity result quality life associate consolidation high-dose cytosine arabinoside compare conventional consolidation/maintenance treatment . III . Determine whether addition granulocyte-macrophage colony stimulate factor ( GM-CSF ) Induction chemotherapy improve therapeutic result activation leukemic cell cell cycle and/or acceleration hematopoietic recovery ( objective add 08/90 ) . IV . Determine indirectly whether autologous bone marrow therapy well conventional consolidation/maintenance high-dose cytosine arabinoside compare result protocol EORTC-06863 ( AML 8 A ) . OUTLINE : Patients normal kidney function randomize Arms A-D Induction ( patient whose serum creatinine 1.5 x upper limit normal nonrandomly assign Arm A ) . Following Induction , patient achieve CR randomize Arms I II . Induction : Arm A : 2-Drug Combination Chemotherapy . Daunorubicin , Daunomycin , DNM , DNR , NSC-82151 ; Cytosine arabinoside , ARA-C , NSC-63878 . Arm B : 2-Drug Combination Chemotherapy plus Growth Factor Therapy . DNM ; ARA-C ; plus Granulocyte-Macrophage Colony Stimulating Factor ( Sandoz ) , GM-CSF . GM-CSF day 0 7 . Arm C : 2-Drug Combination Chemotherapy Hematologic Toxicity Attenuation . DNM ; ARA-C ; GM-CSF . GM-CSF end chemotherapy day 28 . Arm D : 2-Drug Combination Chemotherapy plus Growth Factor Therapy Hematologic Toxicity Attenuation . DNM ; ARA-C ; GM-CSF . GM-CSF day 0 28 . Arm I : Intensive Consolidation : 2-Drug Combination Chemotherapy follow 2-Drug Combination Chemotherapy . High-dose ARA-C , HDARA-C ; Acridinylanisidide , m-AMSA , AMSA , NSC-249992 ; follow HDARA-C ; DNR . Arm II : Standard Consolidation/Maintenance : 2-Drug Combination Chemotherapy . ARA-C ; DNR . PROJECTED ACCRUAL : A minimum 157 patient require ; expect entry rate 40 patient per year , patient entry expect take 4 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Amsacrine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose , untreated acute myelogenous leukemia ( AML ) , follow : Any cytological type accord FAB classification At least 30 % blast cell bone marrow smear require Secondary acute leukemia eligible , i.e . : AML cure Hodgkin 's disease malignancy AML follow exposure alkylating agent radiation The follow specifically exclude : Blast crisis chronic myeloid leukemia Leukemia supervene myeloproliferative disease Leukemia supervene overt myelodysplastic disorder ( e.g. , refractory anemia excess blast ) 6 month ' duration PATIENT CHARACTERISTICS : Age : 4560 Patients 1045 eligible EORTC06863 Performance status : Not specify Hematopoietic : Not specify Hepatic : No severe concomitant hepatic disease Renal : No severe concomitant renal disease Cardiovascular : No severe concomitant cardiac disease Other : No severe concomitant neurological disease No progressive malignant disease PRIOR CONCURRENT THERAPY : Biologic therapy : No prior therapy Chemotherapy : No prior chemotherapy Endocrine therapy : No 7 day corticosteroid AML Radiotherapy : No prior radiotherapy Surgery : Not applicable</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
</DOC>